Fig. 1

Quality of life trajectory up to 37.5 months following treatment measured by QLQ-C30 (A–D) and QLQ-PR25 (E and F) sub-scales. For the QLQ-C30, the blue and pink regions indicate a small and medium clinically important worsening of quality of life, respectively, as previously defined by Cocks et al. 2011 [26]. For the QLQ-PR25, pink regions indicate a minimum 10-point clinically important worsening of quality of life. Small and transient clinically important reductions in global health status (A) and physical functioning (B) were observed at 7.5 months post-treatment as well as small increases in constipation (C) and diarrhoea (D) symptom scores at 13.5 and 7.5 months, respectively. No clinically important changes from baseline were observed for overall urinary (E) or bowel (F) sub-scales